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ABSTRACT - Although the world’s population is ageing and as a result of this an increasing number of 
patients are experiencing difficulty in swallowing, there remains a lack of commercially available oral 
liquids for both these older and paediatric patients. This presents a problem to health care professionals, 
especially the pharmacist in practice, who is often required to provide a solution for these patients by 
preparing oral liquids extemporaneously from commercially available products. Preparation of these oral 
liquids is challenging, both due to the lack of pharmacopoeial and stability-indicating formulae and the fact 
that their stability is not only determined by the active pharmaceutical ingredient, but also the ability of 
excipients from the commercial product to interact with each other and the active pharmaceutical ingredient. 
This increases the complexity of the stability considerations to be taken into account within these oral 
liquids, highlighting the number of parameters to be considered in the extemporaneous preparation of oral 
liquids. 
This paper presents new evidence on the stability of 42 oral liquids prepared from commercially 
available products, reported on in the literature since the previous review published in 2006. However, 
unlike the previous review where the stability concerns in 7.2% of the extemporaneously prepared oral 
liquids were mainly due to interaction between the active pharmaceutical ingredients and the excipients in 
the commercial product, most of these stability considerations have been recognised and this has resulted in 
the authors proposing solutions to these problems prior to the extemporaneous preparation of the oral liquid. 
As such this paper also focuses on the increased level of research that has been undertaken to solve 
previous issues related to stability, especially in terms of the use of commercial products, which is common 
practice in the extemporaneous preparation of oral liquids. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________
  
INTRODUCTION 
 
The lack of commercially available oral liquid 
dosage forms is an ongoing problem for health 
care providers in many practice settings. 
Pharmacists are often challenged to provide 
extemporaneous oral liquids. While these are 
most commonly provided for paediatric patients 
where non-standard doses are more easily and 
accurately measured by using a liquid 
formulation, adults unable to swallow tablets or 
capsules and patients receiving medicines via 
nasogastric or gastrostomy tubes will also benefit 
from these preparations (1). The world’s 
population is ageing and many people suffer from 
dysphagia either as a consequence of disease or as 
part of the ageing process. Elderly patients are 
more prone to diseases linked to dysphagia, such 
as Parkinson’s disease and Alzheimer’s and other 
dementias, stroke and cancer (2-4). 
Extemporaneous oral liquids are also needed 
where, for example, a commercially available oral 
liquid is discontinued or temporarily unavailable, 
such as Tamiflu® (oseltamivir) Oral Suspension 
(5,6). 
A number of parameters need to be 
considered in the formulation of a stable oral 
liquid. These include chemical, physical, 
microbiological, therapeutic and toxicological 
stability evaluations not only taking account of 
the active pharmaceutical ingredient (API), but 
also the excipients and packaging of the drug 
product. The extemporaneous preparation of oral 
liquids can be complex due to the addition of 
excipients to improve patient adherence and / or 
the stability of the final product. Further, due to 
convenience and availability of ingredients, it is 
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common practice for oral liquids to be prepared 
from commercially available solid dosage forms 
such as a tablet or capsules. Therefore additional 
potential interactions may occur between the drug 
and the excipients in the solid dosage in the 
prepared oral liquid. 
In addition to chemical stability, physical 
stability, microbial stability and palatability, 
excipient suitability (e.g. sugar free for diabetic 
patients) and interactions with packaging 
materials need to be considered in the preparation 
of a suitable extemporaneous oral liquid. These 
considerations are detailed in the discussion. 
This review provides new evidence, since the 
previous review in 2006 (7), of stability data for 
extemporaneous oral liquids prepared from 
commercially available dosage forms including 
tablets, capsules and intravenous preparations. 
Further, the review outlines important stability 
considerations and the risk associated with 
modifying commercial products and provides 
guidelines to assist the pharmacist in preparing 
safe, effective and high quality oral liquids.  
 
METHODS 
 
A review protocol was developed with data 
identified from MEDLINE, EMBASE, Informit, 
Google Scholar, reference texts related to the field 
and reference lists of articles and abstracts from 
conference proceedings. Searches were current as 
of April 2013.  
Only those liquid dosage forms prepared from 
commercially available dosage forms were 
considered, as this is most commonly encountered 
in practice, where access to raw material as the is 
not often convenient or even possible. As in the 
first review (7), only those preparations that 
included a chemical stability assessment via a 
stability-indicating high performance liquid 
chromatography (HPLC) method were included 
and the oral liquids were considered chemically 
stable if they retained ≥ 90% of the initial drug 
concentration. The reasons for this are detailed in 
the previous review (7). Those oral liquids that 
have been previously reported on in the first 
review have not been included in this paper. 
 
RESULTS 
 
This review includes 42 examples (Table 1) of 
oral liquids in practice, prepared by modification 
of commercial medications, including the 
methods, excipients, packaging and reasons for 
their extemporaneous preparation. The outcome 
of the chemical and physical stability studies 
conducted is also presented. The highlighted 
(shaded) areas in Table 1 indicate those 
preparations that have been further detailed in the 
discussion.  
 
DISCUSSION 
 
Of the 42 liquid dosage forms reviewed in the 
literature, all cases of instability were managed 
through the addition of specific excipients, 
illustrating that there is minimum risk associated 
with these dosage forms and that pharmacists 
taking cognisance of various factors such as drug 
stability, mechanisms and routes of degradation, 
and potential interactions with excipients in the 
tablets and/or capsules utilised in the formulation 
are further able to minimise the risk involved. The 
individual dosage forms displaying stability 
concerns are discussed below.  
 
Omeprazole and lansoprazole oral liquid 
dosage forms 
Stability concerns with lansoprazole (20) are 
related to a slightly acidic pH of the final formula 
due to Ora-Blend being buffered to a slightly 
acidic pH of ~4.2. However, this instability has 
been largely addressed by the addition of 
NaHCO3. Further, omeprazole is now 
commercially available as a powder for oral 
suspension (ZEGERID® Powder for Oral 
Suspension) which contains NaHCO3, xylitol, 
sucrose, sucralose, xanthan gum, and flavourings. 
 
Mercaptopurine oral liquid dosage forms 
A study reported on the stability of 
mercaptopurine, a drug susceptible to oxidation, 
resulting in the formation of acidic degradants 
(23). A buffer was therefore investigated to 
address the increased acidity due to the formation 
of these degradants. However the buffer resulted 
in a decreased stability of mercaptopurine, due to 
the increased pH. This stability issue was 
addressed by the addition of the antioxidant 
ascorbic acid which increased the shelf-life from 
5 to 11 weeks. 
The authors recommended further studies on 
the microbial safety of these vehicles, since they 
did not contain preservatives; however this can be 
addressed by using commercially available 
vehicles such as Ora-Blend which are adequately 
preserved. 
 
Temozolomide oral liquid dosage forms 
Temozolomide is a prodrug, which after 
hydrolysis in an alkaline environment is 
converted to the active alkylating agent. Solid-
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state temozolomide is thus also susceptible to 
hydrolytic degradation under accelerated 
temperature and humidity conditions (40 ⁰C and 
75% relative humidity), with a change in colour 
of the white powder first to pink and then brown, 
an indication that this chemical degradation has 
occurred.  Temozolomide does however also 
exhibit polymorphism, with powder X-ray crystal 
structures confirming the identity of three 
crystalline polymorphs and a monohydrate. 
Although the powder X-ray diffraction pattern of 
the commercially available temozolomide is 
consistent with Form 1, which is non hygroscopic 
the discolouration of certain brands of tablets on 
storage raises the question as to which crystal 
form is present in these tablets (47). 
Temozolomide oral liquid extemporaneously 
prepared from commercially available capsules in 
both (1:1) Ora-Plus: Ora-Sweet and Ora-Plus: 
Ora-Sweet SF was stored at room temperature (23 
ºC) and at 4 ºC (36), with stability confirmed for 1 
week in Ora-Plus: Ora-Sweet (1:1) and 2 weeks in 
Ora-Plus: Ora-Sweet SF at room temperature (23 
ºC) and 60 days at 4⁰C. Because of the potential 
for polymorphism and the detection of crystals in 
the suspensions within a few days of storage at 
both temperatures, the excipient povidone K-30 
was added to minimise this crystal growth, which 
if it does occur may result in inaccurate dosing. 
The inclusion of povidone K-30 to prevent 
crystal formation and optimising the pH at 4 
(citric acid) to reduce hydrolytic degradation 
produced a pharmaceutically acceptable 
suspension when stored under refrigeration.  
 
Clopidogrel oral liquid dosage forms  
Skillman et al (14) evaluated the stability of 
clopidogrel 5 mg/mL suspension prepared in Ora-
Plus and Ora-Sweet and concluded that over 90 % 
of the initial clopidogrel concentration was 
retained after 60 days at room temperature or 
under refrigeration. However, the method used to 
measure clopidogrel concentration was not 
chirally selective and failed to consider the 
potential for isomeric inversion of the active S-
clopidogrel to the inactive R-clopidogrel. A later 
study (14) highlighted the importance of the 
conversion of the acive S form to the inactive R 
enatiomer. This study determined that 1.5 % and 
3 % of S-clopidogrel was converted to the R 
enantiomer after storage for 49 days at 4 ºC and 
25 ºC respectively. These authors then used this 
data to estimate the shelf-life assuming 90 % of 
the original content and recommended an expiry 
of 1 month under refrigeration and 2 weeks at 
room temperature (25 ºC). 
 
Packaging used in extemporaneous oral liquid 
preparations 
Ensom et al (19) reported on the stability of 
lansoprazole (3mg/mL) in extemporaneously 
compounded suspensions (see Table 2). The 
findings reported here are in contrast with those 
of a previous study (48) detailed in the first 
review (7), in which a lansoprazole suspension (3 
mg/mL) was stable for only 8 hours when 
prepared from capsule contents mixed in 100 mL 
of 8.4% NaHCO3 and stored at room temperature 
(22°C) in amber-coloured, plastic oral syringes. 
Although the refrigerated (4°C) samples in that 
study were reported to be stable for only 14 days, 
the refrigerated samples in the current study were 
stable for 91 days. It has been suggested by the 
authors that the different storage containers, 
namely plastic syringes and glass bottles, may 
account for the difference in stability of 
lansoprazole suspensions, and that a substance 
present in the plastic syringes but not in the glass 
might have reduced the stability of lansoprazole. 
In addition it was also suggested that the amber 
syringes stored at room temperature would not 
have protected the lansoprazole from UV light to 
the same extent as the suspension stored in the 
refrigerator, where it is naturally dark (19).  
  
Storage conditions for oral liquids 
It is important to note that refrigerated solutions 
do not always show increased stability and can 
have increased problems of caking as 
demonstrated by the study by Aliabadi et al (23) 
with a refrigerated suspension of mercaptopurine. 
This emphasises the importance of stability 
studies for specific drugs and the benefits of using 
a vehicle containing appropriate suspending 
agents.  
 
Considerations in the extemporaneous 
preparation of oral liquids 
When considering the suitability of an 
extemporaneous oral liquid, a number of factors, 
in addition to chemical stability need to be 
considered (Table 2). This includes physical 
stability, microbial stability, palatability, excipient 
suitability (e.g. sugar free for diabetic patients), 
interactions with packaging materials, accurate 
compounding procedures including calculations 
and cost. 
 
 
 
J Pharm Pharm Sci (www.cspsCanada.org) 16(3) 441 - 455, 2013 
 
 
 
444 
Table 2. Considerations for the preparation of a stable, effective, quality oral liquid
Consideration Potential excipients required 
Chemical stability Including the stability of the API and the effect 
of tablet excipients in solution; pH stability and 
the need for buffers. 
Antioxidants 
EDTA 
Buffers 
Physical stability Caking, crystal growth, resuspension and the 
ability to administer an accurate dose. 
Suspending agents 
Antifoaming agents 
Microbial stability and 
shelf-life 
Adequate preservation. Preservatives 
Palatability Sufficient masking of bitter drugs. Sweeteners 
Flavours 
Colours 
Excipient suitability  Alcohol free for paediatric patients; sugar free 
for diabetic patients.
Alcohol free vehicles 
Artificial sweeteners 
Packaging Light protection; child safety; interactions with 
packaging materials (glass or plastic). 
 
Bioavailability Absorption and therapeutic efficacy of a drug in 
a suspension compounded from crushed tablets 
is unlikely to differ appreciably from those of 
the original dosage form.
 
Cost Availability of starting materials; staff 
preparation time. 
 
Compounding 
considerations 
Accurate measurement; appropriate equipment 
and facilities; exposure of sensitive ingredients 
(to light) during compounding; water source (no 
ions).  
 
Shelf-life Assigning an appropriate beyond use date/ shelf 
life. 
 
Dose calculations For example, not accounting for the weight of 
tablet excipients when calculating the weight of 
the API. 
 
 
 
From the Table 2 it can be seen that the design of 
an oral liquid from first principles is a lengthy 
process and would require careful consideration 
of a number of factors: 
 
(i)   chemical stability includes considering 
the potential degradation of the API by 
pathways such as oxidation, hydrolysis, 
photolysis or thermolysis, and any 
potential interactions between the API, 
the excipients in the vehicle, the 
excipients in the original dosage form 
(e.g. tablet or capsule) and the packaging. 
(ii)  physical stability includes considering 
resuspension and the ability to administer 
an accurate dose, antifoaming agents to 
prevent excessive foaming from vigorous 
shaking prior to administering a dose, and 
caking or crystal growth that may arise 
during storage. 
(iii) microbial stability includes the use of 
preservatives at a suitable strength to 
prevent microbial growth in a 
predominantly water based preparation. A 
recent study by Ghulam et al (49), 
showed that various suspending vehicles 
failed the BP 2007 efficacy of 
preservation tests when diluted in ratios 
greater than 1:1, and cautioned that such 
dilution represents a potential biohazard, 
especially to premature, newborn, or 
immunocompromised children. Another 
study by Salgado et al (50) on the 
microbial stability of spironolactone in 
Simple syrup NF, demonstrated the 
importance of the use of preservatives, 
since microbial contamination occurred in 
the preparation, even when stored at low 
temperatures. 
(iv) palatability includes the use of suitable 
flavours and sweeteners to mask bitter 
drugs, especially with young patients. It 
has also been suggested that 
administering chocolate syrup before 
medication administration or mixing the 
preparation with chocolate syrup (1:1 by 
volume) immediately before 
administration is recommended to mask 
the bitter aftertaste and improve 
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palatability, for extremely bitter drugs 
(18,28,30). 
(v) excipient suitability includes limiting 
cosolvents such as alcohol for children 
and providing sugar free preparations for 
diabetic patients. 
(vi) packaging includes the use of amber 
containers not only for APIs sensitive to 
light, but also those ingredients in the 
vehicle, such as colours and flavours that 
may also be sensitive to light. Provision 
of child safety packaging is particularly 
important for oral liquids where a 
significant dose could be inadvertently 
administered when compared to tablets or 
capsules. 
(vii) bioavailability. It has been suggested 
that absorption and therapeutic efficacy of 
a drug in a suspension compounded from 
crushed tablets is unlikely to differ 
appreciably from those of the original 
dosage form (35). Careful consideration 
should be given when using commercial 
products designed for administration via 
another route (e.g. intravenous 
preparations) since there may be 
differences in bioavailability when these 
products are administered orally. 
(viii)cost, compounding considerations and 
shelf-life. The availability of starting 
materials and excipients and staff 
preparation time are important 
considerations (9,51,52), as is access to 
appropriate facilities and equipment and 
accurate calculations of ingredients in the 
final preparation. Some API’s are 
extremely sensitive to light, showing 
significant degradation in only a few 
hours, therefore exposure to light needs to 
be minimised during preparation. The 
source of the water used has also been 
shown to cause problems (53). Assigning 
an appropriate beyond use date or shelf- 
life in the absence of specific stability 
studies is also challenging, with many 
preparations given a very short shelf-life 
for safety purposes.  
(ix) dose calculations. A study on the 
stability of a 1 mg/ml tacrolimus 
suspension (34) has shown that careful 
consideration of the strength of the oral 
liquid (namely 1mg/mL as opposed to 
decimal amounts per mL) will facilitate 
several aspects of clinical care, For 
example, the 1:1 ratio of drug to 
suspension volume will decrease the 
frequency of patient medication errors, as 
it allows for a more simplified and 
straightforward drug administration. This 
will also facilitate easier discharge 
medication instructions or any follow-up 
discharge instruction in the outpatient 
clinic when confirming and verifying 
dosing. Further, incremental dosing with 
the 1 mg/ml suspension allows for more 
accurate adjustment of therapy based on 
monitoring blood levels and paediatric 
dosing could result in better patient 
adherence owing to the small volume 
required for dosing. 
 
Commercially available oral liquid vehicles 
Commercially available vehicles, such as Ora-
Plus and Ora-Sweet and Ora-Sweet SF are a 
convenient resource for pharmacists, since many 
practice settings may not stock a wide variety of 
excipients and many of the stability studies in the 
literature on oral liquids prepared 
extemporaneously utilise these commercial 
vehicles, as seen in Table 1. A number of 
medicines are stable at an acidic pH, for example 
thalidomide is not stable in a solution with a pH 
of greater than or equal to 6.0 (37). All of the 
above vehicles are buffered to a slightly acidic pH 
(pH~4.2) to reduce the degradation of medicinal 
agents through oxidation. The vehicles also 
contain effective preservatives, therefore 
microbial testing is not needed (22). Ora-Plus is a 
translucent, milky white oral suspending vehicle 
that can be diluted up to 50 % or more with other 
ingredients and still retain appropriate properties 
as a suspending agent. It also contains an anti-
foaming agent, simethicone, to allow for vigorous 
shaking of the suspension with minimal 
production of foam. Ora-Sweet syrup is a 
flavouring vehicle for oral extemporaneous 
preparations. It contains glycerin and sorbital to 
prevent “cap-lock”, a problem associated with 
many syrups, due to sugar crystallization, and will 
retain its flavouring properties when diluted up to 
50% with water or suspending agents. Ora-Sweet 
SF is a sugar-free version of Ora-Sweet with 
similar properties. Ora-Plus and either Ora-Sweet 
or Ora-Sweet SF can be combined in a 50/50 ratio 
to produce a pleasant tasting elegant suspension. 
The original formulas for the Ora-range of 
vehicles are available in the United States 
Pharmacopoeia/ National Formulary (USP/NF) 
and are referred to as Vehicle for Oral Solution 
NF (i.e. Ora-Sweet), Vehicle for Oral Suspension 
NF (i.e. Ora-Plus), and Vehicle for Oral Solution, 
Sugar Free NF (i.e. Ora-Sweet SF) (54). 
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A recent study (55) on the content uniformity 
of six different suspensions compounded from 
nifedipine tablets, showed that the suspensions 
compounded with methylcellulose 1% / syrup NF 
or hypromellose 1% required mixing by inverting 
the bottle 10 to15 times, while the commercially 
available suspension vehicles (namely, Ora-
Plus/Ora-Sweet, Ora-Plus/Ora-Sweet SF and 
SyrSpend SF Cherry) complied with the 
pharmacopoeial content uniformity test if the 
bottle was inverted only three times. This 
highlights the benefits of utilising commercially 
available vehicles. 
Further usefulness of commercially available 
vehicles is highlighted in a review of the stability 
of captopril oral liquids (53). Due to the 
susceptibility of captopril to oxidation, the use of 
water-based captopril solutions is not 
recommended. This is due to the potential for the 
variable quality of water, particularly in terms of 
its metal ion content, to facilitate the oxidative 
degradation of captopril. The previous review (7) 
detailed a number of studies and the associated 
stability concerns with compounding captopril 
oral liquids. It has been suggested that alternative 
therapeutic agents such as lisinopril and ramipril 
should be preferentially used due to their 
improved stability in oral formulations, or 
commercially available captopril oral liquids 
sourced. 
 
Management of oral liquid preparations in 
practice 
A recent review by Lam (56) on the 
extemporaneous preparation of oral liquid 
formulations for anticancer drugs showed that 
compounding formulae are available for only 46 
% of oral anticancer agents and that there is a 
paucity of data in terms of stability, 
bioequivalence, and safety of these 
extemporaneously prepared oral formulations. 
The review detailed the challenges that health 
care providers, patients, and caregivers face with 
the limited availability of oral liquid formulations. 
Caregivers are often at an increased risk of 
exposure to these hazardous drugs when 
challenged with an oral tablet or capsule that the 
patient cannot swallow. The review also 
highlighted the important role that oncology 
pharmacists, as well as community pharmacists, 
can play as a resource for educating and 
monitoring patients receiving oral chemotherapy 
to ensure dosing accuracy, safe administration, 
and proper disposal of hazardous drugs. 
The first review provided a flow chart, with 
explanations, for the management of oral liquids 
in practice (7). Due to the complexities involved 
in extemporaneously preparing oral liquids, it 
highlighted that (i) pharmacists should always 
consider a commercially available product (i.e. 
this may not necessarily be limited to an oral 
liquid and may include other alternative dosage 
forms, such as a transdermal patch or a dispersible 
tablet); (ii) if no suitable commercial product 
exists, a therapeutic alternative that is available in 
a suitable dosage form may be considered, in 
consultation with the prescribing doctor, and (iii) 
the importation of suitable oral liquid medicines 
licensed in other countries may also be 
considered. 
Should none of these measures prove 
successful, a suitable formula for an oral liquid 
with a proven stability profile should be sought in 
the literature. Useful resources include, Allen’s 
Compounded Formulations (57), Paediatric Drug 
Formulations (58), Trissel’s Stability of 
Compounded Formulations (1), journals such as 
the International Journal of Pharmaceutical 
Compounding and the American Journal of 
Health-System Pharmacy, and the current and 
previous review article (7) showing examples of 
oral liquid dosage forms prepared by modifying 
an existing commercial medication. 
Stability studies in the literature allow for 
increased shelf-life and cost savings, in addition 
to providing evidence for stable products. Further, 
the recent availability of commercial liquid 
vehicles in many countries now provides 
pharmacists with a convenient resource for 
preparing an oral liquid formulation. It is also 
promising to note that procedures to prepare 
stable oral liquids from commercial solid dosage 
forms have been provided by manufacturers in 
cases where an oral liquid is not available or 
temporarily out of stock (Table 3). 
 
Alternatives to preparing oral liquids 
The previous review (7) provided details on 
dispersing tablets or capsules in water or mixing 
them with food immediately prior to 
administration, and the provision of powder 
packets in cases where the preparation of oral 
liquid dosage forms are not feasible. The 
disadvantages of these methods were outlined, 
namely potential for dosing inaccuracies, poor 
palatability leading to adherence issues, and risks 
associated with carers or patients crushing tablets 
which should not be crushed (e.g. sustained 
release tablets).  
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Table 3. Examples of instructions provided by manufacturers for the preparation of oral liquids 
Drug Product 
with reference 
API  Excipients Packaging Stability study data 
Tamiflu® (59,60) Oseltamivir 2 vehicles: Cherry Syrup; 
Ora-Sweet SF 
Amber plastic 
bottle 
6 mg/mL suspension 
stable for 35 days at 2-8 
ºC and 5 days at 25 ºC. 
Zestril®, 
Prinivil® (61,62) 
Lisinopril Vehicle: Purified water, 
Bicitra® diluent and Ora-
Sweet SF®   
Polyethylene 
terephthalate 
(PET) bottle 
1 mg/mL suspension 
stable for four weeks at 
25 ºC. 
Rifadin® (63) Rifampin 4 vehicles:  Simple Syrup 
NF; Simple Syrup (Humco 
Laboratories); Syrpalta® 
Syrup (Emerson 
Laboratories); or 
Raspberry Syrup (Humco 
Laboratories) 
Amber glass or 
plastic (high 
density 
polyethylene, 
polypropylene, or 
polycarbonate) 
prescription bottle 
10 mg/mL suspension 
stable for four weeks at 
2-8 ºC and 25 ± 3 ºC. 
 
 
The review by Lam (56) provides detailed 
guidelines in an Appendix for patients on what to 
do if they cannot swallow their oral anticancer 
medication. 
 
Solid dosage forms that should not be crushed 
Information on the appropriateness of crushing 
tablets or opening capsules is available through 
resources such as the approved product 
information and the CMI (Consumer Medicine 
Information) of the commercial solid dosage 
form. Compiled lists of medicines that should not 
be crushed or modified are available, such as the 
Australian Don’t Rush to Crush Handbook (64), 
the Handbook of Drug Administration via Enteral 
Feeding Tubes (65), the Australian Medicines 
Handbook (AMH) Aged Care Companion (66) 
and electronic resources such as the list provided 
by the Institute for Safe Medication Practices 
(67). 
 
Short term stability of crushed medicines in food 
thickeners or water 
 A recent study reported on the short term 
compatibility of risedronate sodium tablets with 
different food thickeners, namely Milani Thick-
it®, Resource Thicken Up®, Thik & Clear®, 
Hormel Thick & Easy®, and Hormel NutraThik® 
(68). A risedronate sodium 35-mg tablet was 
added to a beaker and allowed to disintegrate 
without agitation. After two minutes, the water 
was stirred with a plastic spoon and an additional 
4 oz of water was added to each beaker and stirred 
briskly for 30 seconds. The recommended amount 
of each food thickener was then added to each 
beaker. The risedronate tablets were shown to be 
stable for 24 hours with each of the food 
thickeners. 
 
CONCLUSION  
 
Orals liquids for certain drugs are often not 
commercially available, due to market size and 
the many physicochemical factors that need to be 
considered when formulating a liquid dosage 
form (69).  Since the physicochemical stability of 
a drug does not confirm either its safety or 
efficacy in a patient, there are a number of factors, 
including exercising good judgement, that the 
pharmacist must take into account when deciding 
to compound an oral liquid (70). The fact that the 
stability of an extemporaneous formulation 
prepared from commercially available products 
cannot be predicted based on a formulation using 
the pure drug powder, due to the effect of 
excipients, was highlighted in the previous review 
where 6 out of 83 (7.2%) oral liquids presented 
with stability concerns, largely due to drug-
excipient interactions. This review, which 
includes 42 oral liquids extemporaneously 
prepared by modifying existing commercial 
dosage forms presents 6 out of the 42 orals liquids 
including the four APIs, clopidrogrel, 
lansoprazole , temozolomide, and mercaptopurine 
for discussion. 
However, it must be noted that the research 
and skill base in compounding has evolved since 
the previous review and that many improvements 
have been made to address the various 
formulation and stability issues in preparing 
extemporaneous oral liquids, from commercially 
available products, which is now common 
practice. 
This review thus presents more complex 
stability issues, where the authors have proposed 
the inclusion of specific ingredients (excipients) 
to address some of the stability problems that 
have been identified in the past, including: the pH 
J Pharm Pharm Sci (www.cspsCanada.org) 16(3) 441 - 455, 2013 
 
 
 
448 
adjustment of lansoprazole extemporaneous oral 
liquids by the addition of NaHCO3 and the 
commercial availability of an oral suspension; the 
inclusion of antioxidants in mercaptopurine oral 
liquid; the addition of povidone K-30 to prevent 
crystal growth and citric acid to optimise pH in 
temozolomide oral liquid; and the adjustment of 
storage conditions to prevent enantiomeric 
conversion of clopidogrel. 
This improved understanding of the role of 
excipients in the stability of extemporaneously 
prepared oral liquids from commercially available 
products will allow the pharmacist to meet the 
challenge in making an informed judgement when 
asked to address the needs of patients requiring 
the compounding of oral liquids. 
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Table 1 Oral liquid dosage forms prepared by modification of commercial medications 
API with reference
  
Extemporaneous 
modification 
Excipients Packaging Stability study data Stability considerations  
How? Why? 
Acetylcysteine (8) 1e 2a, 2c Vehicle: bacteriostatic 0.9% 
sodium chloride for injection. 
3b (amber) 4a. 10 mg/mL and 100 mg/mL 
solutions were stable for 60 days 
at 20-25 ºC.   
API sensitive to oxidation. 
Note inhalation solution 
contains EDTA. 
Acetylcysteine (9) 1e 2a None. Bulk inhalation preparation 
repackaged into oral syringes.  
3c 4a. 600mg/3mL solution was 
stable for 6 months at 3-5 ºC and 
23-25 ºC. 
 
Acetylcysteine (10) 1e * Vehicle: 1:1 Sweetener and 
strawberry creamsicle flavouring 
(FLAVORx Inc). 
3b (amber) 4a. 86.5 mg/mL solution was 
stable for 35 days at 3-5 ºC and 
23-25 ºC. 
Offensive smell and taste 
was effectively masked. 
Aprepitant (11) 1b 2a Vehicle: Ora-Blend 3a (amber); 
3b (amber) 
4a. 20-mg/mL suspension was 
stable for 90 days at 4 ºC in amber 
glass or plastic. Storage at 23 ºC 
accelerated degradation of the 
API. 
 
Celecoxib (12) 1b 2a, 2b Vehicle: Ora-Blend 3b (amber) 4a. 10 mg/mL suspension was 
stable for 93 days at 5 ºC and 23 
ºC. 
 
Clopidogrel (13) 1a 2a Vehicle: 1:1 Ora-Sweet: Ora- 
Plus. 
3b (amber) 4a. 5 mg/mL suspension was 
stable for 60 days at 2-8 ºC and 
23-25 ºC. 
Bitter aftertaste intensified 
slightly between 28-60 
days, but remained fairly 
mild. 
Clopidogrel (14) 1a 2a Vehicle: 1:1 Ora-Sweet: Ora- 
Plus. 
3a (amber) 1 mg/mL suspension was stable 
for 1 month at 4 ºC and 2 weeks at 
25 ºC. 
 
Clozapine (15) 1a 2d 6 vehicles: Ora-Sweet; Ora-Plus; 
1:1 Ora-Sweet: Ora-Plus; Simple 
syrup; ‘Hospital for Sick Children 
suspending vehicle’; and ‘Guy’s 
pediatric mixture’. 
3b (amber) 4a. 20 mg/mL suspensions were 
stable for 63 days at 
 23 ºC. 
 
Cyclophosphamide 
(16) 
1d 2a 2 vehicles: Simple syrup; and 
Ora-Plus.  
3c (amber) 4a. 10 mg/mL solutions were 
stable for 56 days at 4 ºC. Storage 
at 22 ºC in Simple syrup and Ora-
Plus reduced stability to 8 and 3 
days respectively. 
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Dexamethasone 
phosphate (17) 
1d 2a, 2b Vehicle: 1:1 Ora-Sweet: 
Ora-Plus. 
3b (amber) 4a.0.5 and 1.0 mg/mL 
suspensions were stable for 91 
days at 4 ºC and 25 ºC. 
Commercially available 
liquids contain alcohol or 
their strength is lower than 
desirable. 
Glycopyrrolate (18) 1a 2a 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and 1:1 Ora-Sweet 
SF: Ora-Plus. 
3b (amber) 4a. 0.5 mg/mL suspensions were 
stable for 90 days at 23-25 ºC. 
 
Lansoprazole (19) 1b 2d 2 vehicles: NaHCO3, water; 1st 
vehicle + Ora-Sweet:Ora-Plus 
buffered with NaOH 
3a (amber) 4a. 3 mg/mL suspensions were 
stable for 91 days at 4 ºC and 25 
ºC. 1st vehicle developed a more 
bitter taste by day 49, however 
this is for nasogatric and not oral 
use. 
A 3rd vehicle similar to the 
2nd vehicle but buffered 
with NaHCO3 was 
deemed unpalatable. 
Lansoprazole (20) 1a 2d Vehicle: Ora Blend Clear glass 
vial stored 
protected 
from light. 
4a. 3 mg/mL suspension was 
stable for 3 days at 4.5-5.5 ºC. 
Storage at 21-22 ºC or the 
reduction of pH through addition 
of citric acid accelerated 
degradation of the API. 
 
Levetiracetam (21) 1a 2a, 2b Vehicle: 1:1 Ora-Sweet: 
Ora-Plus. 
3b (amber) 4a. 50 mg/mL suspensions were 
stable for 91 days at 4 ºC and 25 
ºC. 
 
Melatonin (22) 1a 2a 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and 1:1 Ora-Sweet 
SF: Ora-Plus. 
3b (amber) 1 mg/mL suspensions were stable 
for 90 days at 23-25 ºC. Slight 
yellow colouring occurred over 
time. 
 
Melatonin and 
pyridoxine HCl (22) 
1a 2a 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and 1:1 Ora-Sweet 
SF: Ora-Plus. 
3b (amber) 1 mg/mL (melatonin) suspensions 
were stable for 90 days at 23-25 
ºC. Slight yellow colouring and 
prolonged aftertaste occurred over 
time. 
 
Mercaptopurine (23) 1a 2a 4 vehicles: simple syrup, cherry 
syrup, water; 1st vehicle + 
ascorbic acid; 1st vehicle + 
sodium phosphate; and 1st vehicle 
+ ascorbic acid and sodium 
phosphate. 
3a (amber) 50 mg/mL suspensions were 
stable for 35 days at 19-23 ºC. 
Formulations stored in a 
refrigerator (4-8 ºC) showed 
decreased stability and caking. 
Further studies on the microbial 
safety and efficacy of these 
vehicles were suggested.
API sensitive to oxidation, 
especially at basic pH. 
Antioxidant (0.1% 
ascorbic acid) increased 
shelf life, whereas buffer 
(sodium phosphate) 
decreased shelf-life. 
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Moxifloxacin (24) 1a 2d 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and 1:1 Ora-Sweet 
SF: Ora-Plus. 
3b (amber) 4a. 20 mg/mL suspensions were 
stable for 90 days at 23-25 ºC. 
 
Omeprazole (25) 1f 2d Vehicle: water. 3b (amber) 4a. 2 mg/mL suspension was 
stable for 45 days at 3-5 ºC. At 45 
days, there was a very slight 
yellowish tint in all samples, 
which were creamy white when 
first prepared. 
 
Omeprazole (26) 1f 2d Vehicle: water. Clear plastic 
50mL 
conical 
polypropyle
ne tubes 
4a. 0.6, 1.2, 2, 3 and 4 mg/mL 
suspensions were stable for 28 
days at 4 °C (in the dark). Except 
for the 0.6 mg/mL preparations, 
suspensions stored at 22-25 ºC in 
the light were stable for 7 days, 
despite turning yellow. 
 
Oseltamivir (6)  1b 2e 2 vehicles: Cherry Syrup and Ora-
Sweet SF. 
3a (amber); 
3b (amber) 
4a. 15-mg/mL suspensions were 
stable for 35 days at 5 ºC. 2nd 
vehicle was also stable for 35 
days at 25 ºC and for up to 13 
days at 30 ºC.   
 
Oseltamivir (5) 1b 2e 3 vehicles: SyrSpend SF; Cherry 
Syrup; and SyrSpend SF (for 
reconstitution). 
3b (amber) 4a.15-mg/mL suspensions were 
stable for 30 days at 2-8 ºC.  
Vehicles are ethanol- and 
sorbitol-free. 
Oxandrolone (27) 1a 2a 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and 1:1 Ora-Sweet 
SF: Ora-Plus. 
3b (amber) 4a. 1 mg/mL suspensions were 
stable for 90 days at 23-25 ºC. 
Women who are or may 
become pregnant should 
wear a mask when 
compounding. 
Phenobarbital (28) 1a 2a 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and 1:1 Ora-Sweet 
SF: Ora-Plus. 
3b (amber) 4a. 10 mg/mL suspensions were 
stable for 115 days at 23-25 ºC. 
Commercially available 
liquid contains alcohol. 
Phenylbutyrate (29) 1f 2a 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and 1:1 Ora-Sweet 
SF: Ora-Plus. 
3b (amber) 4a. 200 mg/mL suspensions were 
stable for 90 days at 23-25 ºC. 
Both preparations were 
bitter with a strong, bitter 
aftertaste. 
Rifaximin (30) 1a 2d 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and 1:1 Ora-Sweet 
SF: Ora-Plus. 
3b (amber) 4a. 20 mg/mL suspensions were 
stable for 60 days at 23-25 ºC. 
 
Rufinamide (31) 1a 2a, 2b 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and 1:1 Ora-Sweet
3b (amber) 4a. 40 mg/mL suspensions were 
stable for 90 days at 23-25 ºC.
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SF: Ora-Plus. 
Sulfasalazine (32) 1a 2a, 2b Vehicle: 1:1 Ora-Sweet: Ora-Plus. 3a (amber); 
3b (PET and 
PVC) 
(amber)  
100 mg/mL suspensions were 
stable for 91 days at 4 ºC and 23 
ºC 
 
Sunitinib (33) 1b 2a, 2b Vehicle: 1:1 Ora-Sweet: Ora- 
Plus. 
3b (amber) 4a. 10-mg/mL suspension was 
stable for 60 days at 4 ºC and 
22ºC.  
 
Tacrolimus (34) 1b  2a, 2b Vehicle: sterile water, 1:1 Ora-
Sweet: Ora-Plus. 
3b (amber) 4a. 1 mg/mL suspension was 
stable for 4 months at 23-26ºC. 
 
Tadalafil (35) 1a 2a, 2b Vehicle: 1:1 Ora-Sweet: Ora- 
Plus. 
3b (amber) 4a. 5 mg/mL suspension was 
stable for 91 days at 23-25 ºC. 
 
Temozolomide (36) 1b 2a, 2b 2 vehicles: citric acid, povidone 
K-30, 1:1 Ora-Sweet: Ora-Plus; 
and citric acid, povidone K-30, 
1:1 Ora-Sweet SF: Ora-Plus. 
3b (amber) 4a. 10 mg/mL suspensions were 
stable for 60 days at 4 ºC. 
Storage at 23 ºC 
accelerated degradation of 
the API. 
Thalidomide (37) 1b 2d Vehicle: 1:1 Ora-Sweet: Ora- 
Plus. 
3b (amber) 4a. 20 mg/mL suspension was 
stable for 35 days at 3-5 ºC. 
Caregivers administering 
the liquid should avoid 
contact with the skin. 
Wear gloves and a mask 
when compounding. 
Thalidomide (38) 1b 2d Vehicle : tragacanth mucilage, 
sorbitol compound syrup, benzoic 
acid 5% solution, citric acid, 
distilled water. 
Amber 
bottles 
4a. 10 mg/mL suspensions were 
stable for 31 days at 21-23 ºC. 
See warnings above 
regarding protective 
measures. 
Thioguanine (39) 1a 2a 3 vehicles: Simple syrup and 
methylcellulose; Ora-Sweet and 
Ora-Plus; and 2nd vehicle + 
ascorbic acid. 
3a (amber) 20 mg/mL suspensions were 
stable for 63 days at 19-23 ºC. pH 
increased over the study period.  
Addition of antioxidant 
(0.1% ascorbic acid) was 
not effective in 
consistently increasing 
shelf-life. 
Vancomycin (40)  1d 2a, 2b Vehicle: SyrSpend SF 3b (amber) 50 mg/mL suspension was stable 
for 90 days at 2-8 ºC. 
Vehicle is ethanol- and 
sorbitol-free. 
Venlafaxine (41) 1b 2d 2 vehicles: 1:1 Ora-Sweet: 
Ora-Plus; and Simple syrup. 
3b (amber) 4a. 15mg/mL suspension was 
stable for 28 days at 5 ºC and 23 
ºC. 
The capsules were a slow 
release dosage form. 
Capsule microspheres 
were ground to a powder. 
Venlafaxine (42) 1a 2a, 2b Vehicle: 1:1 Ora-Sweet: Ora- 
Plus. 
3a (amber) 4a. 5mg/mL suspension was 
stable for 15 days at 4 ºC and 10 
days at 22-28 ºC. 
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Venlafaxine (43) 1b 2c 2 vehicles: tragacanth mucilage, 
sorbitol compound syrup, benzoic 
acid 5% solution, distilled water; 
and 1st vehicle without tragacanth 
mucilage. 
3a (amber) 4a. 7.5 mg/mL suspensions were 
stable for 30 days at 20-24 ºC. 
The capsules were a slow 
release dosage form. 
Capsule microspheres 
were ground to a powder. 
Warfarin (44) 1a 2d Vehicle: Sodium phosphate, 
tragacanth mucilage, sorbitol 
compound syrup, Compound 
Hydroxybenzoate Solution APF 
(methyl and propyl 
hydroxybenzoate, propylene 
glycol), distilled water. 
3a (amber) 4a. 1 mg/mL suspensions were 
stable for 28 days at 20-24 ºC. 
Warfarin is subject to pH-
dependent sorption to 
polyvinyl chloride plastic. 
(1) 
Ziprasidone mesylate 
(45) 
1d 2a Vehicle: Ora-Sweet. 3b (amber) 4a. 2.5 mg/mL solution was stable 
for 6 weeks at 5 ºC. Storage in the 
light or at 20-22 ºC accelerated 
degradation of the API. 
The API is solubilised by 
complexation with β-
cyclodextrin in the I/V 
preparation. 
Zonisamide (46) 1b 2d 2 vehicles: Simple syrup NF; and 
0.5 % methylcellulose. 
3b (amber) 4a. 10 mg/mL suspension was 
stable for 28 days at 3-5 ºC and 
23-25 ºC in the 1st vehicle, and 28 
days at 3-5 ºC and 7 days at 23-25 
ºC in the 2nd vehicle. 
Significant microbial 
growth was observed in 
methylcellulose vehicle 
stored at 23-25 ºC after 7 
days. 
1a. Tablet modified to an oral liquid mixture  
1b. Capsule modified to an oral liquid mixture  
1c. Liquid-filled soft gelatin capsule modified to an oral liquid mixture  
1d. I/V preparation modified to an oral liquid mixture  
1e. Inhalation preparation modified to an oral liquid mixture 
1f. Granular powder preparation modified to an oral liquid mixture 
2a. Lack of a commercially available oral liquid (paediatric) formulation for dose adjustment according to body weight or swallowing difficulties 
2b. Ease of administration due to swallowing difficulties 
2c. Nasogastric, jejunal, or feeding tubes 
2d. All of the above – i.e. oral liquid dosage form not commercially available; including patients requiring a non-standard dose. 
2e. Commercial oral liquid dosage form discontinued or unavailable 
* Unpleasant sulfurous smell and taste of the drug resulting from the slow release of hydrogen sulfide gas. As a result, patients may experience nausea and vomiting 
and have difficulties adhering to either oral or inhalation therapy. 
3a. Glass prescription bottles 
3b. Plastic prescription bottles 
3c. Plastic oral syringes 
4a. Analysis of organoleptic properties (e.g. colour, odour, taste) and visual inspection of physical stability (e.g. signs of caking, ease of pouring/ redistribution, 
microbial growth) and analysis of apparent pH revealed no appreciable changes throughout the storage period. 
